A simple statistical analysis of the accumulated and daily numbers of new COVID-19 cases and deaths per capita was performed with the use of recent datasets for European and some other countries and regions. It was shown that vaccination can significantly reduce the likelihood of deaths. However, existing vaccines do not prevent new infections, and vaccinated individuals can spread the infection as intensely as unvaccinated ones. Therefore, it is too early to lift quarantine restrictions in Europe and most other countries. The constant appearance of new cases due to re-infection increases the likelihood of new coronavirus strains, including very dangerous. As existing vaccines are not able to prevent this, it remains to increase the number of tests per registered case. If the critical value of 520 is exceeded, one can hope to stop the occurrence of new cases.
Competing Interest Statement
The authors have declared no competing interest.
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv